Immunonutritional consequences of different serine-type protease inhibitors in a C57BL/6 hepatocarcinoma model.
hepatocarcinoma
immunonutrition
innate immunity
macrophage
serine-type protease inhibitors
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
22 Jan 2019
22 Jan 2019
Historique:
received:
13
11
2018
accepted:
09
01
2019
entrez:
19
2
2019
pubmed:
19
2
2019
medline:
19
2
2019
Statut:
epublish
Résumé
Imbalances in innate immunity and the activity of innate immune cells are implicated in the development of hepatocellular carcinoma (HCC). Plant seeds are good sources of protease inhibitors, which can have a significant influence on human health disorders, especially in the field of cancer prevention. To elucidate the impact and preventive effects of immunonutritional serine-type protease inhibitors (STPIs) on HCC, it was used an established model of chemically induced liver injury. Injured livers induced Akt as well as hepatic infiltration of NKG2D
Identifiants
pubmed: 30774778
doi: 10.18632/oncotarget.26605
pii: 26605
pmc: PMC6366820
doi:
Types de publication
Journal Article
Langues
eng
Pagination
760-772Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST Authors do not have conflicts of interest to declare.
Références
J Immunol. 2001 Nov 15;167(10):5583-93
pubmed: 11698429
J Immunol. 2004 Feb 15;172(4):2001-5
pubmed: 14764662
J Exp Med. 2005 May 16;201(10):1615-25
pubmed: 15883173
Blood. 2006 May 1;107(9):3727-32
pubmed: 16391018
Hepatology. 2006 Feb;43(2 Suppl 1):S145-50
pubmed: 16447291
Oncogene. 2006 Jun 26;25(27):3801-9
pubmed: 16799621
J Endotoxin Res. 2007;13(2):94-100
pubmed: 17621550
Development. 1991 Jun;112(2):517-26
pubmed: 1794320
Blood. 2008 Nov 15;112(10):4080-9
pubmed: 18753637
BMC Cancer. 2009 Aug 05;9:270
pubmed: 19656379
Biochem Pharmacol. 2010 Feb 1;79(3):373-80
pubmed: 19766599
J Immunol. 2010 Sep 1;185(5):2773-82
pubmed: 20675592
BJU Int. 2011 Feb;107(4):678-9
pubmed: 21276178
Lab Invest. 2011 Nov;91(11):1615-23
pubmed: 21863061
Hepatology. 2012 Jul;56(1):291-9
pubmed: 22278715
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Cancer Cell. 2012 Apr 17;21(4):504-16
pubmed: 22516259
Clin Dev Immunol. 2012;2012:836485
pubmed: 22737174
J Clin Oncol. 2012 Oct 20;30(30):3697-704
pubmed: 23008316
J Exp Med. 2012 Dec 17;209(13):2395-408
pubmed: 23209313
J Hepatol. 2013 Nov;59(5):1007-13
pubmed: 23796475
Hepat Med. 2010 Mar;2010(2):39-47
pubmed: 23997575
Br J Nutr. 2015 Nov 14;114(9):1395-402
pubmed: 26344377
Int J Clin Exp Med. 2015 Jul 15;8(7):10746-52
pubmed: 26379867
Gastroenterology. 2016 Jun;150(7):1646-1658.e17
pubmed: 26924089
Nat Rev Dis Primers. 2016 Apr 14;2:16018
pubmed: 27158749
Food Chem Toxicol. 2016 Sep;95:89-95
pubmed: 27377345
Bull Exp Biol Med. 2016 Aug;161(4):495-500
pubmed: 27597056
Cell Mol Life Sci. 2017 Feb;74(4):715-730
pubmed: 27628304
Sci Rep. 2016 Oct 03;6:34252
pubmed: 27694815
Inflamm Res. 2017 Mar;66(3):209-216
pubmed: 27752708
Nat Commun. 2016 Dec 22;7:13817
pubmed: 28004654
Front Pharmacol. 2016 Dec 08;7:470
pubmed: 28008315
Oncoimmunology. 2016 Nov 1;5(12):e1252012
pubmed: 28123894
Nat Commun. 2017 Jan 27;8:13930
pubmed: 28128200
Nat Commun. 2017 Jul 17;8:16073
pubmed: 28714465
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Front Immunol. 2017 Oct 26;8:1383
pubmed: 29123526
Exp Mol Med. 2017 Dec 8;49(12):e408
pubmed: 29217822
Eur J Clin Invest. 2018 Feb;48(2):e12870
pubmed: 29235098
Nature. 2018 Feb 8;554(7691):255-259
pubmed: 29364878
Sci Rep. 2018 Apr 18;8(1):6220
pubmed: 29670256
Eur J Clin Invest. 2018 Nov;48 Suppl 2:e12989
pubmed: 29956819
Cell Death Dis. 2018 Jul 9;9(7):763
pubmed: 29988030
J Cell Biochem. 2018 Nov;119(11):9419-9432
pubmed: 30015355
Int J Oncol. 2018 Oct;53(4):1580-1590
pubmed: 30066851
Sci Rep. 2018 Oct 18;8(1):15394
pubmed: 30337619
Eur J Immunol. 1981 Oct;11(10):805-15
pubmed: 7308288